ERBB2 and breast carcinoma: In this study, we try our best to explore the efficacy and safety of EC combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer, which may be an economic and effective therapeutic strategy for neoadjuvant therapy of HER2 positive breast cancer.